Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse

[1]  M. Jerkeman,et al.  Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden , 2021, Blood cancer journal.

[2]  R. Advani,et al.  CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions , 2020 .

[3]  Sunita Ghosh,et al.  Lack of Effectiveness of Intravenous High-Dose Methotrexate for Prevention of CNS Relapse in Patients with High-Risk DLBCL: A Retrospective Analysis from Alberta, Canada , 2020 .

[4]  S. Booth,et al.  Stand‐alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R‐CHOP and is associated increased infection‐related toxicity , 2019, British journal of haematology.

[5]  J. Huh,et al.  Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis , 2019, International Journal of Hematology.

[6]  L. Sehn,et al.  Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. , 2019, Blood.

[7]  N. Goldschmidt,et al.  Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse , 2019, Leukemia & lymphoma.

[8]  Yu Zhao,et al.  Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure , 2018, Cancer science.

[9]  L. Sehn,et al.  Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. , 2018, European journal of cancer.

[10]  M. Gleeson,et al.  Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  R. Gascoyne,et al.  Diffuse large B‐cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era , 2017, British journal of haematology.

[12]  R. Gascoyne,et al.  CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Vignati,et al.  Risk‐tailored CNS prophylaxis in a mono‐institutional series of 200 patients with diffuse large B‐cell lymphoma treated in the rituximab era , 2015, British journal of haematology.

[14]  Scott E. Smith,et al.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. , 2014, Blood.

[15]  Michael L. Wang,et al.  Double hit lymphoma: the MD Anderson Cancer Center clinical experience , 2014, British journal of haematology.

[16]  S. Opat,et al.  A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma , 2014, British Journal of Cancer.

[17]  R. Tibshirani,et al.  A multicentre study of primary breast diffuse large B‐cell lymphoma in the rituximab era , 2014, British journal of haematology.

[18]  L. Gordon,et al.  Lack of benefit of central nervous system prophylaxis for diffuse large B‐cell lymphoma in the rituximab era , 2012, Cancer.

[19]  N. Schmitz,et al.  CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. , 2012 .

[20]  A. López-Guillermo,et al.  First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  K. Morris,et al.  Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma , 2011, Cancer.

[22]  P. Hammerman,et al.  Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma , 2010, Cancer.

[23]  N. Schmitz,et al.  CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). , 2009, Blood.

[24]  T. Molina,et al.  Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. , 2003, Blood.

[25]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.